Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis.

Koblinski JE, Kaplan-Singer BR, VanOsdol SJ, Wu M, Engbring JA, Wang S, Goldsmith CM, Piper JT, Vostal JG, Harms JF, Welch DR, Kleinman HK.

Cancer Res. 2005 Aug 15;65(16):7370-7.

2.

Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer.

Mitra A, Fillmore RA, Metge BJ, Rajesh M, Xi Y, King J, Ju J, Pannell L, Shevde LA, Samant RS.

Breast Cancer Res. 2008;10(2):R22. doi: 10.1186/bcr1874. Epub 2008 Mar 7.

3.

Effects of raf kinase inhibitor protein expression on metastasis and progression of human breast cancer.

Li HZ, Gao Y, Zhao XL, Liu YX, Sun BC, Yang J, Yao Z.

Mol Cancer Res. 2009 Jun;7(6):832-40. doi: 10.1158/1541-7786.MCR-08-0403. Epub 2009 Jun 16.

4.

Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.

Chang XZ, Li DQ, Hou YF, Wu J, Lu JS, Di GH, Jin W, Ou ZL, Shen ZZ, Shao ZM.

Breast Cancer Res. 2007;9(6):R76.

5.

Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells.

Lee WJ, Chen WK, Wang CJ, Lin WL, Tseng TH.

Toxicol Appl Pharmacol. 2008 Jan 15;226(2):178-91. Epub 2007 Sep 21.

PMID:
17961621
6.

Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.

Moore LD, Isayeva T, Siegal GP, Ponnazhagan S.

Clin Cancer Res. 2008 Aug 1;14(15):4961-70. doi: 10.1158/1078-0432.CCR-07-4604.

7.

Targeting matrilysin and its impact on tumor growth in vivo: the potential implications in breast cancer therapy.

Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mason MD, Mokbel K, Mansel RE.

Clin Cancer Res. 2005 Aug 15;11(16):6012-9.

8.

Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer.

Palmieri D, Halverson DO, Ouatas T, Horak CE, Salerno M, Johnson J, Figg WD, Hollingshead M, Hursting S, Berrigan D, Steinberg SM, Merino MJ, Steeg PS.

J Natl Cancer Inst. 2005 May 4;97(9):632-42.

PMID:
15870434
9.

The LCC15-MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype.

Sung V, Gilles C, Murray A, Clarke R, Aaron AD, Azumi N, Thompson EW.

Exp Cell Res. 1998 Jun 15;241(2):273-84.

PMID:
9637769
11.

Roles of osteonectin in the migration of breast cancer cells into bone.

Campo McKnight DA, Sosnoski DM, Koblinski JE, Gay CV.

J Cell Biochem. 2006 Feb 1;97(2):288-302.

PMID:
16173048
12.

Stromelysin-3 over-expression enhances tumourigenesis in MCF-7 and MDA-MB-231 breast cancer cell lines: involvement of the IGF-1 signalling pathway.

Kasper G, Reule M, Tschirschmann M, Dankert N, Stout-Weider K, Lauster R, Schrock E, Mennerich D, Duda GN, Lehmann KE.

BMC Cancer. 2007 Jan 17;7:12.

13.

Matrix metalloproteinase-1 is a crucial bone metastasis factor in a human breast cancer-derived highly invasive cell line.

Okuyama N, Matsumine A, Kosugi R, Wakabayashi H, Uchida A.

Oncol Rep. 2008 Dec;20(6):1497-504.

PMID:
19020733
14.
15.

Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo.

Bendre MS, Gaddy-Kurten D, Mon-Foote T, Akel NS, Skinner RA, Nicholas RW, Suva LJ.

Cancer Res. 2002 Oct 1;62(19):5571-9.

16.
17.

[Duffy antigen receptor for chemokines attenuates breast cancer growth and metastasis: an experiment with nude mice].

Wang J, Ou ZL, Hou YF, Luo JM, Chen Y, Zhou J, Shen ZZ, Ding J, Shao ZM.

Zhonghua Yi Xue Za Zhi. 2005 Aug 3;85(29):2033-7. Chinese.

PMID:
16313795
18.

Role of interleukin-8 in the progression of estrogen receptor-negative breast cancer.

Yao C, Lin Y, Ye CS, Bi J, Zhu YF, Wang SM.

Chin Med J (Engl). 2007 Oct 20;120(20):1766-72.

PMID:
18028768
19.

Downregulation of SPARC expression inhibits cell migration and invasion in malignant gliomas.

Seno T, Harada H, Kohno S, Teraoka M, Inoue A, Ohnishi T.

Int J Oncol. 2009 Mar;34(3):707-15.

PMID:
19212676
20.

Supplemental Content

Support Center